Our portfolio company Therini Bio has reached a significant clinical milestone with the dosing of the first patient in their Phase 1b trial evaluating THN391, a first-in-class monoclonal antibody for Alzheimer's disease treatment.

THN391 represents a pioneering approach targeting chronic neuroinflammation through selective fibrin epitope binding, addressing underlying vascular dysfunction in neurodegeneration.

The randomized, double-blind, placebo-controlled trial will assess safety, tolerability, and pharmacokinetics in early Alzheimer's patients aged 65-85 with vascular risk factors, with initial data expected mid-2026. This breakthrough therapy, which demonstrated excellent safety and monthly dosing convenience in Phase 1a trials, could transform treatment paradigms for Alzheimer's and other neurodegenerative diseases driven by inflammatory processes.

Read the complete press release